Principal Investigator
Carl Landgren
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20221148
Clinical Trial Summary
Phase
Phase II
Funding Agency/Sponsor
Institutional
Disease
Myeloma
Contact Information
Phone Number
305-243-2647